Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • ALS Biopharma, Biohaven deal

    ALS Biopharma LLC, Doylestown, Pa. Biohaven Pharmaceutical Holding Co. Ltd., Tortola, Virgin Islands Business: Neurology, Cancer, Other Biohaven purchased from ALS Biopharma worldwide rights to IP covering more than 300…

    Published on 10/5/2015
  • Arvinas, Genentech, Roche deal

    Arvinas LLC, New Haven, Conn. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Proteomics Arvinas granted Roches Genentech unit rights to develop new therapeutics …

    Published on 10/5/2015
  • Biogen, Columbia University, The ALS Association deal

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Columbia University, New York, N.Y. The ALS Association, Washington, D.C. Business: Neurology, Genomics Biogen, the universitys medical center and the association partnered to…

    Published on 10/5/2015
  • BioMarin, Serono deal

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Serono S.A., Geneva, Switzerland Business: Endocrine/Metabolic BioMarin will regain rights to phenylketonuria (PKU) treatments Kuvan sapropterin …

    Published on 10/5/2015
  • BioNovion, Aduro Biotech deal

    BioNovion B.V., Oss, the Netherlands Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Business: Cancer, Antibodies Aduro will acquire BioNovion for EUR14.5 million ($16.2 million) in cash and EUR14.5 million in Aduro …

    Published on 10/5/2015
  • BioQuiddity, Lees Pharmaceutical Holdings Ltd. deal

    BioQuiddity Inc., San Francisco, Calif. Lees Pharmaceutical Holdings Ltd. (HKSE:0950), Hong Kong, China Business: Neurology, Drug delivery BioQuiddity granted Lees Pharmaceutical rights to commercialize ropivacaine and …

    Published on 10/5/2015
  • Cadiogen, Audentes Therapeutics deal

    Cardiogen Sciences Inc., Palo Alto, Calif. Audentes Therapeutics Inc., San Francisco, Calif. Business: Cardiovascular Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains …

    Published on 10/5/2015
  • Cardiome, Eddingpharm deal

    Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, B.C. Eddingpharm Inc., Shanghai, China Business: Cardiovascular Cardiomes Correvio International S.a.r.l. subsidiary granted Eddingpharm exclusive rights to …

    Published on 10/5/2015
  • Chromocell, Astellas deal

    Chromocell Corp., North Brunswick, N.J. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Neurology Chromocell granted Astellas exclusive, worldwide rights to develop and commercialize the biotechs CC8464 and …

    Published on 10/5/2015
  • Daktari Diagnostics, Merck deal

    Daktari Diagnostics Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Diagnostic Daktari and Merck partnered to develop Daktaris Daktari HCV screening test in a deal that Daktari says is …

    Published on 10/5/2015
  • Eisai, Purdue Pharma deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Purdue Pharma L.P., Stamford, Conn. Business: Neurology Eisais Eisai Inc. subsidiary and Purdue partnered to develop and commercialize Eisais lemborexant (E2006) to treat …

    Published on 10/5/2015
  • Erasmus University Rotterdam, MDxHealth deal

    Erasmus University Rotterdam, Rotterdam, the Netherlands MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic Erasmus granted MDxHealth exclusive, worldwide rights to use bladder cancer DNA methylation …

    Published on 10/5/2015
  • Galapagos, AbbVie, Abbott deal

    Galapagos N.V. (Euronext:GLPG;NASDAQ:GLPG), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Autoimmune AbbVie declined to exercise its option to …

    Published on 10/5/2015
  • Infinity, AbbVie deal

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer Infinity received a $130 million milestone payment from AbbVie under a 2014 deal granting the pharma …

    Published on 10/5/2015
  • neuroFix Therapeutics, Medgenics deal

    neuroFix Therapeutics LLC, Philadelphia, Pa. Medgenics Inc. (NYSE-M:MDGN), Wayne, Pa. Business: Neurology Medgenics acquired neuroFix for $2 million in cash and more than $481 million in potential milestones. neuroFix …

    Published on 10/5/2015
  • Peregrine, AstraZeneca deal

    Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Tustin, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer The companies partnered to evaluate Peregrines bavituximab with AstraZenecas durvalumab (…

    Published on 10/5/2015
  • QIMR Berghofer Medical Research Institute, Bristol-Myers deal

    QIMR Berghofer Medical Research Institute, Brisbane, Australia Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Autoimmune, Cancer Bristol-Myers and QIMR partnered to discover therapeutic antibodies against…

    Published on 10/5/2015
  • Regeneron Pharmaceuticals Inc, Mitsubishi Tanabe Pharma deal

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Business: Autoimmune Regeneron granted Mitsubishi exclusive rights to develop and commercialize …

    Published on 10/5/2015
  • Theratechnologies, BL&H deal

    Theratechnologies Inc. (TSX:TH), Montreal, Quebec BL&H Co. Ltd., Seoul, South Korea Business: Endocrine/Metabolic Theratechnologies granted BL&H rights to develop and commercialize Egrifta tesamorelin in South Korea to …

    Published on 10/5/2015
  • Valneva, Kaketsuken deal

    Valneva SE (Euronext:VLA;VSE:VLA), Lyon, France Kaketsuken, Kumamoto, Japan Business: Infectious Valneva granted Kaketsuken non-exclusive rights to develop a human vaccine using Valnevas EB66 cell line. Valneva is …

    Published on 10/5/2015
  • Vanderbilt University, La Jolla Pharmaceutical deal

    Vanderbilt University, Nashville, Tenn. La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Business: Pharmaceuticals La Jolla and the university partnered to develop small molecule kinase inhibitors discovered…

    Published on 10/5/2015
  • Xoma, Novartis deal

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Antibodies Xoma granted Novartis exclusive, worldwide rights to develop and commercialize its antibody program …

    Published on 10/5/2015
  • Yale University, Allied Minds, Bristol-Myers deal

    Yale University, New Haven, Conn. Allied Minds plc (LSE:ALM), Boston, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Yale granted Allied-Bristol Life Sciences LLC, a JV between Allied Minds …

    Published on 10/5/2015
  • 4D Pharma, University College Cork deal

    4D Pharma plc (LSE:DDDD), Manchester, U.K. University College Cork, Cork, Ireland Business: Neurology 4D partnered with the universitys APC Microbiome Institute to research live biotherapeutics to treat autism and …

    Published on 9/28/2015
  • AcelRx, Gruenenthal, PDL BioPharma deal

    AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), Redwood City, Calif. Gruenenthal Group, Aachen, Germany PDL BioPharma Inc. (NASDAQ:PDLI), Incline Village, Nev. Business: Neurology AcelRx sold to PDL a portion of the …

    Published on 9/28/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993